ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) saw a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 9,200 shares, an increase of 5.7% from the August 31st total of 8,700 shares. Based on an average daily volume of 13,500 shares, the short-interest ratio is presently 0.7 days.
Institutional Investors Weigh In On ProShares Ultra Nasdaq Biotechnology
Several hedge funds have recently added to or reduced their stakes in BIB. Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of ProShares Ultra Nasdaq Biotechnology in the 1st quarter worth approximately $288,000. Westwood Wealth Management bought a new stake in ProShares Ultra Nasdaq Biotechnology in the first quarter worth $575,000. Toth Financial Advisory Corp boosted its position in ProShares Ultra Nasdaq Biotechnology by 132.3% during the first quarter. Toth Financial Advisory Corp now owns 26,111 shares of the exchange traded fund’s stock valued at $1,502,000 after buying an additional 14,870 shares during the period. Finally, Clarity Capital Partners LLC bought a new position in shares of ProShares Ultra Nasdaq Biotechnology during the fourth quarter valued at about $201,000.
ProShares Ultra Nasdaq Biotechnology Price Performance
Shares of NASDAQ:BIB traded down $0.11 during trading on Monday, reaching $63.08. The company had a trading volume of 9,946 shares, compared to its average volume of 25,434. The company has a fifty day moving average of $65.13 and a two-hundred day moving average of $59.66. ProShares Ultra Nasdaq Biotechnology has a 12 month low of $40.10 and a 12 month high of $69.56.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
ProShares Ultra Nasdaq Biotechnology Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Read More
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- 3 Stocks to Consider Buying in October
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- What is an Earnings Surprise?
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Trading Stocks: RSI and Why it’s Useful
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.